An immunotoxin is a macromolecular drug which consists of a monoclonal antibody linked to a protein toxin. The antibody transports the toxin in the body and selectively targets it to tumour cells by binding to a cell-surface antigen expressed uniquely or at elevated levels on the tumour compared with normal tissues. The toxin then enters the cell and incapacitates it by irreversibly blocking an essential metabolic process.
A unique combination of three properties distinguishes immunotoxins from other forms of antibody-targeted therapy (Embleton, 1987; Bagshawe, 1989; Epenetos & Kosmas, 1989; Wawrzynczak & Davies, 1990) . First, the potent cytocidal action of immunotoxins is independent of any secondary agent or host accessory mechanisms. Second, immunotoxins are not harmful to non-malignant cells unless they bind inadvertantly and can be internalised efficiently. Third, the mechanisms by which immunotoxins intoxicate cells are quite distinct from those exploited by conventional chemotherapeutic drugs or radiation treatments.
Experimental studies of monoclonal antibodies armed with toxins have gathered momentum in recent years for two main reasons: first, the failure of standard therapeutic strategies to improve treatment in many different malignancies and second, the generally disappointing results of immunotherapy trials with unarmed monoclonal antibodies. Immunotoxins against most of the common human cancers have been described, many exert a potent and selective cytotoxic action against tumour cells in culture and in animal models of malignancy, and several are in clinical trials (reviewed in Vitetta et al., 1987; Blakey et al., 1988b; Frankel, 1988; Blattler et al., 1989; .
Toxin structure and action
The protein toxins employed in immunotoxins are complex and highly potent molecules whose ultimate action is the inactivation of protein synthesis within target cells (Figure 1 ). The bacterial toxins, diphtheria toxin (DTX) and Pseudomonas exotoxin (PE), inactivate the eukaryotic elongation factor-2 (EF-2). The toxins derived from plants, ricin and abrin, are enzymes that inactivate eukaryotic ribosomes. In every case, intoxication requires that the enzymic portion of the toxin is transferred to the cytosol from an initial binding site on the cell surface and depends on the co-ordinated action of several parts of the toxin molecule with distinct functions (Figure 2 (Ogata et al., 1990) . A second feature of PE important to toxicity is the presence of an amino acid sequence at the C-terminus of the catalytic fragment which resembles the consensus sequence KDEL responsible for signalling the retention of soluble proteins within the endoplasmic reticulum (Chaudhary et al., 1990b (Wawrzynczak et al., 1988 (Wawrzynczak et al., 1991d (Hertler & Frankel, 1989 ).
The largest trial to date has been conducted in over 100 patients with metastatic melanoma treated with a ricin A chain immunotoxin recognising a high molecular weight antigen (Spitler et al., 1989) . Disease stabilisation or mixed responses were observed in about one third of patients following a single course of immunotoxin therapy and there was one complete response. The presence of immunotoxin was demonstrated in tissue samples of metastatic lesions derived from a number of patients. Tumour regression tended to occur in pulmonary, lymph node and soft tissue metastases rather than in abdominal visceral lesions; progression occurred in the non-responding sites and by development of new metastases (Oratz et al., 1990) . Interestingly, the observed regressions took place over a matter of months following immunotoxin therapy.
Seventeen patients with metastatic colon cancer have been treated with a single course of a ricin A chain immunotoxin recognising a 72 kDa tumour-associated antigen in a phase I dose-escalation study . Mixed responses were detected in five patients; three had a decrease in the size of large hepatic metastases and disappearance of smaller lesions, others showed regression of pulmonary and supraclavicular node metastases. In this study also, tumour regressions occurred over the course of several months following treatment.
Two phase I studies of an immunotoxin consisting of recombinant ricin A chain linked to an antibody against a tumour-associated epithelial antigen have been conducted in breast cancer patients (Gould et al., 1989; Weiner et al., 1989 A common feature of all the clinical trials in metastatic cancer was the development of a humoral immune response against the immunotoxin. The majority of patients analysed were found to have generated an IgM and an IgG response to both the toxin and murine antibody components (Durrant et al., 1989; Mischak et al., 1990) . In patients re-infused with the anti-melanoma immunotoxin following the immune response-to initial treatment, the half-life of the immunotoxin was diminished according to the serum titre of reactive IgG but no adverse effects were seen (LoBuglio et al., 1988) . In the patients receiving the anti-colon carcinoma immunotoxin, the predominant response to the antibody was directed against the idiotypic determinants; a component of this response was able to block cell binding by the antibody and, by implication, could inhibit immunotoxin binding (Durrant et al., 1989) .
Further clinical studies of ricin A chain immunotoxins are in progress or are planned using immunotoxins made with monoclonal antibodies recognising the CD5 antigen in cutaneous T cell lymphoma, the CD7 antigen in T-cell acute lymphocytic leukaemia, the CDl9 and CD22 antigens in B-cell tumours, the CD30 antigen in Hodgkin's disease, and the transferrin receptor in patients with tumours restricted to the peritoneal cavity (Ghetie et al., 1988; Hertler et al., 1989b; Engert et al., 1990; Bookman et al., 1990a (Hertler et al., 1989a; Colombatti et al., 1990) . A second approach has been to screen for those monoclonal antibodies recognising the target antigen which mediate the most potent effects . Monoclonal antibodies recognising epitopes situated proximal to the cell membrane can form A chain immunotoxins with substantially higher target cell potency than antibodies having similar immunochemical properties which are directed against more distal epitopes possibly because the A chain is brought into more intimate contact with cellular membranes (Press et al., 1988; May et al., 1990) .
A second restraint on anti-tumour efficacy is immunotoxin stability. The survival of A chain immunotoxins in vivo is influenced by the properties of the A chain and the manner of its attachment to the antibody. Immunotoxins made with native glycosylated A chains are rapidly eliminated from the bloodstream via receptor-mediated recognition by cells of the reticuloendothelial system, predominantly the Kupffer cells of the liver. This carbohydrate-mediated clearance can be avoided by the use of ricin A chain which has been chemically treated to abolish receptor binding, of recombinant ricin A chain from Escherichia coli, or of the aglycosyl abrin A chain Wawrzynczak et al., , 1991a . A chain immunotoxins break down in vivo to release the antibody and A chain constituents because the disulphide linkage, necesssarily included in their construction to maximise activity, is susceptible to reduction by endogenous glutathione. The rate of splitting can be minimised by the use of hindered cross-linking agents, or of abrin A chain, both forming conjugates which are more resistant to breakdown than the conventional type of A chain immunotoxin . A further complication is that disulphide-linked A chain immunotoxins can interact selectively with M2-macroglobulin in vivo by thioldisulphide interchange to form high molecular weight complexes (Ghetie et al., 1991) A novel idea is to attach the A chain stably by means of the DTx polypeptide loop which can be proteolytically cleaved within the target cell to yield an active disulphide-linked A chain derivative (O'Hare et al., 1990) . This tactic could circumvent the premature inactivation of immunotoxin by splitting or complexation.
A third factor influencing the anti-tumour action of immunotoxins is the efficiency with which they localise in tumours. The rate of extravasation of macromolecules is determined in part by molecular size (Figure 3 ). Tumour localisation is significantly enhanced for ricin A chain immunotoxins made with antibody Fab' or F(ab')2 fragments compared with analogous immunotoxins made with intact antibody (Fulton et al., 1988a; Rostaing-Capaillon & Casellas, 1990 ). The molecular size of immunotoxins can also be reduced by selecting smaller toxin components such as asarcin or restrictocin which form immunotoxins having comparable potency to those made with the larger plant-derived toxin A chains or RIPs (Orlandi et al., 1988; Conde et al., 1989; Wawrzynczak et al., 1991c (Stoudemire et al., 1990) . In further clinical trials of the anti-melanoma immunotoxin, attempts have been made to increase the duration of therapy by suppressing the host response with cyclophosphamide, prednisone, azathioprine and cyclosporin A, used singly or in combination (Spitler et al., 1989; Oratz et al., 1990 ). Some immunosuppressive regimens were able to control the response to a single infusion of immunotoxin but not to repeated administration. Another approach is to selectively suppress the action of T helper cells in the immune response. In preliminary studies using a murine model, the administration of monoclonal CD4 antibody completely abrogated the antitoxin response to an immunotoxin (Jin et al., 1991) .
Therapy with intact toxins
The therapeutic use of intact protein toxins has been inhibited by the high toxicity associated in major part with non-specific binding via the natural cell-binding sites of the native toxins. A trial of intraperitoneal therapy with an anti-ovarian carcinoma immunotoxin made with native PE was discontinued due to severe and unexplained neurotoxicity (Bookman et al., 1990b) . The elimination of the Nterminal binding domain (Ia) of PE results in a truncated toxin molecule called PE40. The cytotoxicity of this fragment is decreased by more than 100-fold although PE40 immunotoxins are about 10-fold less potent than their intact PE analogues. Mutagenesis studies have identified four positively-charged amino acid residues of the PE binding domain which contribute to its toxicity in animals; their replacement with negatively-charged glutamic acid residues generates an analogue known as PE664lu which has 150-fold lower toxicity and should therefore be more suitable for therapy (Chaudhary et al., 1990c) .
Removal of a C-terminal 17 kDa portion of DTx comprising the cell-binding domain of the B chain eliminates the non-specific toxicity of a DTx immunotoxin but decreases its target cell toxicity by 100-fold, probably because the remnant B chain is conformationally destabilised. A more useful candidate is a full-size DTx with two amino acid residue replacements in the binding domain. The mutant DTx, called CRM107, has 10,000-fold lower toxicity than native DTx but forms immunotoxins with target cell toxicity equipotent with their native DTx counterparts (Johnson et al., 1988 ). An anti-transferrin receptor immunotoxin made with the DTx CRM 107 mutant has been developed for the treatment of leptomeningeal neoplasms, such as glioblastoma and medulloblastoma which over-express the transferrin receptor, by the intrathecal route of administration (Johnson et al., 1989) .
The galactose-binding sites of ricin become partially occluded following attachment to antibody but the blockade is insufficiently complete to be of value. A blocked ricin having a non-target cell toxicity about 1,000-fold lower than that of the native toxin has been generated by chemically attaching oligosaccharide ligands with a high affinity for the galactosebinding sites (Lambert et al., 1991) . Trials of immunotoxins made with this blocked ricin are in progress or planned to take place in patients with B-cell tumours and small cell lung carcinoma. Genetic engineering of ricin to eliminate the galactose-binding sites has not been possible because the toxin's extreme potency precludes its useful production in eukaryotic expression systems. Instead, ricin A and B chains have been separately cloned and expressed from bacteria in biologically active form. A recombinant B chain with diminished saccharide-binding ability has been generated by substitution of a single binding site amino acid residue (Vitetta & Yen, 1990 ).
Prospects
The principal aim of all cancer therapies is to maximise inhibition of tumour growth and to minimise toxic sideeffects. In common with conventional anti-cancer drugs, improvements in the therapeutic performance of immunotoxins will stem from the development of analogues with improved properties and from a better understanding of the obstacles to their successful action.
Immunotoxins made with native toxins generally have a higher cytotoxic potency than A chain immunotoxins, intoxicate cells more rapidly, and achieve a higher clonogenic cell kill. In the case of intact toxins lacking functional binding sites, which rely on the target antigen for internalisation and cannot exploit the natural route of entry, the advantages are less well documented. Moreover, targeted toxin analogues which are able to kill cells efficiently whatever the pathway of uptake are likely to prove more toxic to cells lacking the target antigen than A chain immunotoxins whose potency is a function of the antigen-mediated pathway of uptake. At present, the best candidates for systemic therapy are potent A chain immunotoxins which can possess a high selectivity of action, greater than 100,000-fold, exceeding that which can be achieved with intact toxins manipulated to minimise binding to natural toxin receptors. Nevertheless, it remains the case that for the majority of target antigens only immunotoxins made with intact toxins have demonstrated sufficient potency to be of therapeutic value. A more detailed understanding of the intracellular fate of A chain immunotoxins and the structural features determining routing and translocation may allow further modifications designed to enhance their intrinsic potency.
The extent of immunotoxin localisation in tumour and hence the likely anti-tumour effect is determined by the blood concentration over time, the rate of extravasation and the degree of penetration. Native DTx administered intravenously is capable of eradicating large solid human tumour masses located in the peritoneal cavity or in the brain parenchyma of experimental animals which are not susceptible to the action of the toxin (Raso & McGrath, 1989; Wrobel et al., 1990) . In contrast, a DTx immunotoxin made with intact antibody extravasates less rapidly than the toxin due to its considerably larger size but can accumulate in the tumour to a higher level because of a comparatively slower rate of blood clearance and higher cell binding (Sung et al., 1990) . A disadvantage of the native toxins, and of their more selective analogues, is that their size cannot be further reduced without substantially diminishing their activity. By comparison, the plant and fungal RIPs are about one half and one quarter the size of the intact toxins respectively, differences that become increasingly significant the further the size of the antibody component is decreased (Figure 3) .
In principle, the size of the antibody component can be reduced by using smaller recognition units than the proteolytically-derived Fab fragments, for example, an Fv domain comprising the heavy and light chain variable domains of a single Fab arm. Indeed, recombinant immunotoxins have been created that consist of a singlechain Fv domain from an antibody recognising the human interleukin-2 receptor in peptidyl linkage to either PE40 or a truncated DTx analogue (Chaudhary et al., 1989; 1990a) . However, the potential advantage of enhanced access to tumour by miniaturised immunotoxins is balanced by two possible disadvantages. First, immunotoxins made with univalent antibody fragments are usually less potent than their bivalent counterparts because they bind to the target cell surface less avidly. Second, the biological half-life of immunotoxins made with antigen-binding fragments of antibody is diminished by the absence of the Fc portion responsible for the regulation of IgG catabolism. The judicious recombination of antibody domains and toxins with the appropriate properties can be expected to evolve immunotoxin molecules of novel design with improved tumour localisation properties.
Toxic side-effects mediated via antigen binding can be minimised by selecting second generation monoclonal antibodies with the highest selectivity for the target tumour and by removing the possibility of non-specific interaction, for example, by selectively modifying regions of the antibody that mediate binding to cellular Fc receptors but are not involved with the control of antibody half-life (Wawrzynczak et al., 1991b) . Further modifications of toxin structure and immunotoxin design by recombinant methods are also likely to minimise cross-reaction with normal tissues. The relationship between immunotoxin pharmacokinetics and toxicity is less well understood. The exposure of normal tissues, and consequently their susceptibility to damage, is increased by prolonging the blood half-life of immunotoxins. However, in therapy experiments, immunotoxins with longer in vivo survival also display superior anti-tumour effects and have an improved therapeutic index compared with shorter-lived analogues (Fulton et al., 1988b; Thorpe et al., 1988) .
The humoral response in Man to mouse antibody can be mitigated by replacing the mouse constant domains and framework regions of the variable domains with the analogous structures derived from human antibody. This strategy does not obviate the anti-idiotypic response, nor, in the case of immunotoxins, the equal problem of the response to the toxin component. An additional problem with the use of the bacterial toxins in Man is that significant numbers of patients, especially those immunised with the BCG vaccine, have a pre-existing immune response to the toxins. Some transient benefit may be expected by engineering out the immunodominant epitopes of the toxin molecules. The best long-term solution to the obstacle of immunogenicity, relevant to immunotoxins and other natural or recombinant therapeutic proteins, is likely to be a strategy able to actively suppress responses to soluble and cell-binding immunogens.
The target antigens which have generally been selected for immunotoxin therapy are expressed by the majority of malignant cells in a tumour. However, the phenomenon of tumour cell heterogeneity is a fundamental limitation to the immunotoxin approach. Malignant cells expressing the target antigen at low levels tend to be less susceptible to immunotoxin and a proportion of tumour cells can be resistant to killing because they fail to internalise surface-bound immunotoxin. This may not be an obstacle to inducing tumour regression provided that immunotoxin treatment inflicts sufficient damage to activate natural host defences. A practical solution is to use immunotoxins in combination with agents that bring about tumour cell killing by different mechanisms. Anti-tumour effects superior to the use of either the immunotoxin or of another agent alone can be achieved in three ways. Firstly, by synthesising radioimmunotoxins that simultaneously target a toxin and a radionuclide (Manske et al., 1988; Ito et al., 1991) . Secondly, by administering immunotoxins in parallel with or following cytoreductive agents such as cyclophosphamide or daunorubicin (Pearson et al., 1989a; Yokota et al., 1990) . Thirdly, by using recombinant human interferon-x either to enhance target cell sensitivity to immunotoxin directly, or to stimulate hostmediated effector mechanisms (Pearson et al., 1990; Yokota et al., 1990) .
Conclusion
Immunotoxins can be administered to Man systemically within acceptable limits to toxicity and can elicit anti-tumour effects in cancer patients with disseminated disease who have failed conventional treatment. Future improvements in clinical performance can be expected from developments in three areas. First, the generation of novel immunotoxins with defined structure having improved potency and selectivity, greater stability, enhanced tumour localisation, lower toxicity and reduced immunogenicity. Second, elucidation of the basic mechanisms responsible for immunotoxin-induced toxicity and immune responses and the invention of novel strategies to minimise the limitations these side-effects place upon therapy. Third, the use of immunotoxins in clinical settings where there is a potential therapeutic advantage of either combination therapy with agents having complementary anti-tumour activities, or second-line therapy when the onset of resistance to conventional treatment first thwarts further clinical benefit. 
